Genmab Past Earnings Performance
Past criteria checks 1/6
Genmab has been growing earnings at an average annual rate of 26.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 33.4% per year. Genmab's return on equity is 10.5%, and it has net margins of 26.4%.
Key information
26.8%
Earnings growth rate
25.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 33.4% |
| Return on equity | 10.5% |
| Net Margin | 26.4% |
| Next Earnings Update | 10 Aug 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genmab makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 9,020 | 2,377 | 1,534 | 4,486 |
| 31 Dec 21 | 8,482 | 3,008 | 1,283 | 4,181 |
| 30 Sep 21 | 7,907 | 2,873 | 1,002 | 3,787 |
| 30 Jun 21 | 7,321 | 2,513 | 841 | 3,394 |
| 31 Mar 21 | 10,800 | 5,585 | 756 | 3,248 |
| 31 Dec 20 | 10,111 | 4,758 | 661 | 3,115 |
| 30 Sep 20 | 11,028 | 5,649 | 546 | 2,880 |
| 30 Jun 20 | 10,344 | 5,656 | 483 | 2,766 |
| 31 Mar 20 | 5,667 | 2,363 | 377 | 2,555 |
| 31 Dec 19 | 5,366 | 2,166 | 342 | 2,386 |
| 30 Sep 19 | 3,641 | 1,528 | 285 | 2,173 |
| 30 Jun 19 | 3,199 | 1,170 | 258 | 1,910 |
| 31 Mar 19 | 2,935 | 1,345 | 241 | 1,664 |
| 31 Dec 18 | 3,025 | 1,472 | 214 | 1,431 |
| 30 Sep 18 | 2,807 | 1,424 | 195 | 1,227 |
| 30 Jun 18 | 2,532 | 1,239 | 177 | 1,112 |
| 31 Mar 18 | 2,796 | 1,286 | 157 | 995 |
| 31 Dec 17 | 2,365 | 1,104 | 147 | 852 |
| 30 Sep 17 | 2,275 | 1,159 | 131 | 795 |
| 30 Jun 17 | 2,316 | 1,354 | 121 | 718 |
| 31 Mar 17 | 1,897 | 1,215 | 110 | 704 |
| 31 Dec 16 | 1,816 | 1,187 | 102 | 661 |
| 30 Sep 16 | 1,463 | 735 | 101 | 642 |
| 30 Jun 16 | 1,376 | 686 | 94 | 606 |
| 31 Mar 16 | 1,196 | 535 | 93 | 529 |
| 31 Dec 15 | 1,133 | 764 | 91 | 488 |
| 30 Sep 15 | 774 | 443 | 92 | 443 |
Quality Earnings: GE9 has a high level of non-cash earnings.
Growing Profit Margin: GE9's current net profit margins (26.4%) are lower than last year (51.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GE9's earnings have grown significantly by 26.8% per year over the past 5 years.
Accelerating Growth: GE9's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GE9 had negative earnings growth (-57.4%) over the past year, making it difficult to compare to the Biotechs industry average (-26.8%).
Return on Equity
High ROE: GE9's Return on Equity (10.5%) is considered low.